Study on the clinical mechanism of Tongxieanchangfang in the treatment of diarrheal irritable bowel syndrome based on single-cell sequencing technology

Dongfang Hospital Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with IBS-D diagnosed by western medicine;
•2. Patients with IBS-SSS score > 75;
•3. Patients with liver depression and spleen deficiency syndrome according to TCM syndrome differentiation;
•4. Patients aged 18-65 years;
•5. Subjects who signed informed consent.

•1. Patients with intestinal organic lesions (colonoscopy or colonoscopy report within 3 months);
•2. Patients with contraindications of colonoscopy;
•3. Patients with severe pathological changes of liver, brain, kidney and other major organs, and patients with mental disorders;
•4. Patients with systemic diseases affecting gastrointestinal motility (such as hyperthyroidism, diabetes, chronic renal insufficiency, etc.);
•5. Pregnant women and lactating women;
•6. The patients who used other drugs to treat irritable bowel syndrome in the first week were screened;
•7. Patients with allergic constitution, and those who are allergic to the known ingredients and any excipients of the drug in this study;
•8. Patients with suspected or true history of alcohol or drug abuse;
•9. Patients who participated in other clinical trials within three months.

发起方

Dongfang Hospital Beijing University of Chinese Medicine